Jazz Pharmaceuticals
Manufacturing · Ireland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Waterloo Exchange Fifth floor Waterloo R...Phone Number
+353 16347800Website
www.jazzpharma.comRevenue
$4.4 BillionStock Symbol
JAZZIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
9
9
1
2
2
2
About Jazz Pharmaceuticals
Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals is a global biopharmaceutical company. The company focuses on products for neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors.Explore more
Jazz Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Jazz Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Jazz Pharmaceuticals launches new products
Check out if Jazz Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Jazz Pharmaceuticals
Check if Jazz Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Jazz Pharmaceuticals recently announced quarterly report
Jazz Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Jazz Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Jazz Pharmaceuticals has new funding data
Recommended Actions
Find VP level buyers at Jazz Pharmaceuticals
Find more new buyers
Compare Similar Companies to Jazz Pharmaceuticals
Compare insights from companies similar to Jazz Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$1.4B
1K - 5K
Private
$18M
1992
SG
Sean GormanDirector, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Company Profile Activity
Activity Insights
Jazz Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Jazz Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Jazz Pharmaceuticals.
Jazz Pharmaceuticals financials insights
Gather financial insights about Jazz Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Series A
$15M
Series B
$250M
2007
Stock Offering
$97.2M
2008
Debt
$75M
Stock Offering
$26M
2009
Share Placement
$7M
2010
Stock Offering
$58.5M
Debt
$50M
2017
Debt
$575M
Jazz Pharmaceuticals Tech Stack
A closer look at the technologies used by Jazz Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Person-Based
Events
Jazz Pharmaceuticals News & Media
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and...Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
For U.S. media and investors only DUBLIN, June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic...Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today...Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Jazz Pharmaceuticals plc (JAZZ) Jefferies Global Healthcare Conference 2026 June 3, 2026 10:30 AM EDTCompany ParticipantsRobert Iannone - Executive VP,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Jazz Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals is a global biopharmaceutical company. The company focuses on products for neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors.... Read More
